Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
FBLG
#3765
FibroBiologics, Inc. Common Stock
0.3
3
+17.86%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+17.86%
Monatliche Änderung
-8.33%
6 month change
-45.90%
Jahresänderung
-72.73%
Vorheriger Schlusskurs
0.2
8
Open
0.3
3
Bid
Ask
Low
0.3
3
High
0.3
3
Volumen
3
Märkte
Aktien
Gesundheitswesen
FBLG
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
33.92 M
35.09 M
37.74 M
40.86 M
48.26 M
66.52 M
193.38 M
Valuation ratios
Enterprise value
99.27 M
70.95 M
25.77 M
17.26 M
23.21 M
10.31 M
76.55 M
Price to earnings ratio
-5.24
-5.88
-4.29
-1.73
-1.14
-0.54
-7.69
Price to sales ratio
—
71.47
—
—
4.73
2.95
—
Price to cash flow ratio
9.33
5.52
2.4
1.49
1.26
0.61
5.77
Price to book ratio
9.56
24.04
2.98
2.48
3.17
1.63
10.26
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.05
0.08
0.43
0.33
0.66
0.34
1.77
Return on equity %
0.18
0.48
2.11
5.42
46.22
0.53
54.28
Return on invested capital %
—
—
—
—
—
-403.37
—
Gross margin %
—
100
100
100
100
100
400
Operating margin %
—
403.37
287.87
244.29
-3 759.7
2 055.56
-1 171.99
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
141.63
315.5
253.43
-4 311.94
2 574.6
-1 168.41
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
1.23
1.12
1.14
0.93
0.78
3.61
6.45
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
0.07
0.11
0.15
-0.01
0.01
0.26
Solvency ratios
Debt to assets ratio
—
0.58
—
—
—
—
—
Debt to equity ratio
—
3.46
—
—
—
—
—
Long term debt to total assets ratio
0.01
0.56
0.51
0.58
0.52
0
1.61
Long term debt to total equity ratio
0.04
3.35
2.48
9.38
36.58
0
48.45
Per share metrics
Operating cash flow per share
0.08
0.09
0.14
0.1
0.09
0.07
0.41
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
0.29
—
—
—
—
—
Cash per share
0.23
0.43
0.24
0.23
0.11
0.11
0.69
Net current asset value per share
0.24
0.43
0.25
0.26
0.12
0.14
0.78
Tangible book value per share
0.08
0.08
0.06
0.02
0
0.14
0.23
Working capital per share
0.05
0.05
0.03
-0.02
-0.03
0.1
0.08
Book value per share
0.08
0.08
0.06
0.02
0
0.14
0.23
Nachrichten
H.C. Wainwright senkt Kursziel für FibroBiologics auf 4 US-Dollar
H.C. Wainwright cuts FibroBiologics stock price target to $4
FibroBiologics: Aktionäre genehmigen Reverse Split und Ausgabe von Aktien aus Optionsscheinen
FibroBiologics shareholders approve reverse stock split and warrant share issuances
FibroBiologics: NASDAQ gewährt Aufschub zur Erfüllung der Listing-Anforderungen
FibroBiologics gets Nasdaq extension to meet listing rules
FibroBiologics erhält Zulassung für klinische Studie zu diabetischem Fußsyndrom in Q1 2026
FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026
FibroBiologics meldet positive Studienergebnisse bei Therapie für Bandscheibendegeneration
FibroBiologics reports positive results for disc degeneration therapy
FibroBiologics droht Delisting von der NASDAQ – Unternehmen beantragt Anhörung
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal